Skip to main content

Guarini Kathryn's Form 4 filing

Regeneron Pharmaceuticals, Inc.REGN · filed Nov 3, 2026

Accession no.
0001992352-26-000009
Filed
Nov 3, 2026, 4:22 PM ET
Trade date
Oct 30, 2026
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $360.0K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Guarini KathrynCIK 0001992352Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 30, 2026Common StockMOption exerciseAcquired+400$719.37+$287,7481,003Direct
Oct 30, 2026Common StockSSaleDisposed−400$900.00−$360,000603Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 30, 2026Common StockMOption exerciseDisposed−400$0.00$0758Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)